Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), HIF-2α inhibitors(Endothelial PAS domain-containing protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Renal Cell Carcinoma | Preclinical | Spain | 17 Jun 2024 | |
| Hepatocellular Carcinoma | Preclinical | Spain | 30 Aug 2023 | |
| Respiratory Diseases | Preclinical | Spain | 30 Aug 2023 | |
| Triple Negative Breast Cancer | Preclinical | Spain | 30 Aug 2023 |





